LLY

984.76

+0.73%↑

JNJ

241.59

-0.56%↓

ABBV

219.68

-2.45%↓

NVS

153.09

-0.73%↓

AZN

190.11

-0.92%↓

LLY

984.76

+0.73%↑

JNJ

241.59

-0.56%↓

ABBV

219.68

-2.45%↓

NVS

153.09

-0.73%↓

AZN

190.11

-0.92%↓

LLY

984.76

+0.73%↑

JNJ

241.59

-0.56%↓

ABBV

219.68

-2.45%↓

NVS

153.09

-0.73%↓

AZN

190.11

-0.92%↓

LLY

984.76

+0.73%↑

JNJ

241.59

-0.56%↓

ABBV

219.68

-2.45%↓

NVS

153.09

-0.73%↓

AZN

190.11

-0.92%↓

LLY

984.76

+0.73%↑

JNJ

241.59

-0.56%↓

ABBV

219.68

-2.45%↓

NVS

153.09

-0.73%↓

AZN

190.11

-0.92%↓

Search

Ionis Pharmaceuticals Inc

Uždarymo kaina

SektoriusSveikatos priežiūra

71.12 -1.59

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

70.81

Max

71.53

Pagrindiniai rodikliai

By Trading Economics

Pajamos

-100M

-229M

Pardavimai

46M

203M

Pelno marža

-112.808

Darbuotojai

1,402

EBITDA

4.7B

4.6B

Rekomendacijos

By TipRanks

Rekomendacijos

Stiprus pirkimas

12 mėnesių prognozė

+34.2% upside

Dividendai

By Dow Jones

Kitas uždarbis

2026-04-29

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

-1.3B

12B

Ankstesnė atidarymo kaina

72.71

Ankstesnė uždarymo kaina

71.12

Naujienos nuotaikos

By Acuity

50%

50%

133 / 351 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Neutral Evidence

Ionis Pharmaceuticals Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-03-15 21:14; UTC

Svarbiausios naujienos

Week Ahead for FX, Bonds: Central Bank Decisions -2-

2026-03-15 21:14; UTC

Svarbiausios naujienos

Week Ahead for FX, Bonds: Central Bank Decisions in Focus After Jump in Energy Prices

2026-03-13 19:08; UTC

Svarbiausios naujienos

TotalEnergies Shutting Production in Qatar, Iraq Amid Fighting in Middle East

2026-03-15 23:45; UTC

Rinkos pokalbiai

Nikkei May Decline on Concerns About Prolonged Middle East Conflict -- Market Talk

2026-03-15 23:44; UTC

Rinkos pokalbiai
Svarbiausios naujienos

Gold Falls as Rising Energy Prices Exacerbate Inflation Worries -- Market Talk

2026-03-15 23:35; UTC

Rinkos pokalbiai
Svarbiausios naujienos

Oil Futures Rise on Supply Disruption Concerns -- Market Talk

2026-03-15 23:00; UTC

Įsigijimai, susijungimai, perėmimai

Micron Completes Acquisition Of PSMC's Tongluo P5 Site In Taiwan >MU

2026-03-15 22:37; UTC

Rinkos pokalbiai

March Rate Hike Would Distance RBA From Government's May Budget -- Market Talk

2026-03-15 22:18; UTC

Rinkos pokalbiai

RBA's Likely Hike Motivated By Inflation, Not Middle East -- Market Talk

2026-03-15 22:14; UTC

Uždarbis

Genscript Biotech 2025 Adj Net $230.35M Vs. Adj Net $59.83M>1548.HK

2026-03-15 22:14; UTC

Uždarbis

Genscript Biotech: 2025 Loss Due to High Base Effect, One-off Unrealized Gains Seen Last Year >1548.HK

2026-03-15 22:14; UTC

Uždarbis

Genscript Biotech 2025 Rev $959.53M Vs. $594.49M >1548.HK

2026-03-15 22:14; UTC

Uždarbis

Genscript Biotech 2025 Loss $532.83M Vs. Net $2.96B >1548.HK

2026-03-15 22:14; UTC

Uždarbis

Genscript Biotech: 2025 Rev Supported by Substantial Increase in License Revenue>1548.HK

2026-03-15 22:00; UTC

Svarbiausios naujienos

Oil Industry Warns Trump Administration Energy Crisis Will Likely Worsen -- WSJ

2026-03-15 22:00; UTC

Svarbiausios naujienos

Oil Industry Warns Trump Administration Energy Crisis Will Likely Worsen -- WSJ

2026-03-15 03:00; UTC

Svarbiausios naujienos

For Xi, Iran War Reinforces View of U.S. as Dangerous Superpower -- WSJ

2026-03-14 15:00; UTC

Svarbiausios naujienos

Iran War Delivers Windfall to America's Oil Country -- WSJ

2026-03-14 02:03; UTC

Uždarbis

This Copper Stock Is Worth Mining for Profits -- Barrons.com

2026-03-14 01:32; UTC

Įsigijimai, susijungimai, perėmimai

Bill Ackman's Pershing Square IPO Is Back On -- Barrons.com

2026-03-14 00:29; UTC

Įsigijimai, susijungimai, perėmimai

13D Filings -- Barrons.com

2026-03-13 22:27; UTC

Rinkos pokalbiai
Svarbiausios naujienos

Bahrain Faces Uncertainty But Has Support Amid War, S&P Says -- Market Talk

2026-03-13 22:13; UTC

Rinkos pokalbiai
Svarbiausios naujienos

Saudi Arabia Seen as Able to Weather Iran Conflict, S&P Says -- Market Talk

2026-03-13 22:04; UTC

Rinkos pokalbiai
Svarbiausios naujienos

Emirate of RAK Outlook Stable Despite Iran War, S&P Says -- Market Talk

2026-03-13 22:00; UTC

Įsigijimai, susijungimai, perėmimai

Trump Administration Set to Receive $10 Billion Fee for Brokering TikTok Deal -- WSJ

2026-03-13 20:50; UTC

Rinkos pokalbiai

Health Care Roundup: Market Talk

2026-03-13 20:50; UTC

Rinkos pokalbiai
Svarbiausios naujienos

Financial Services Roundup: Market Talk

2026-03-13 20:02; UTC

Rinkos pokalbiai

Canada Rate Hike in 2026 Would Mark 'Extraordinarily Bad' Policy -- Market Talk

2026-03-13 19:50; UTC

Rinkos pokalbiai
Svarbiausios naujienos

Oil Posts Weekly Gains As Middle East Conflict Drags On -- Market Talk

2026-03-13 19:35; UTC

Svarbiausios naujienos

Oil Prices Hover Near $100. India Asks Iran to Allow 23 Tankers Through Strait of Hormuz. -- Barrons.com

Akcijų palyginimas

Kainos pokytis

Ionis Pharmaceuticals Inc Prognozė

Kainos tikslas

By TipRanks

34.2% į viršų

12 mėnesių prognozė

Vidutinis 95.54 USD  34.2%

Aukščiausias 110 USD

Žemiausias 72 USD

Remiantis 14 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Ionis Pharmaceuticals Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

14 ratings

11

Pirkti

3

Laikyti

0

Parduoti

Techninis įvertinimas

By Trading Central

29.78 / 33.645Palaikymas ir pasipriešinimas

Trumpalaikis periodas

Neutral Evidence

Vidutinės trukmės periodas

Very Strong Bullish Evidence

Ilgalaikis periodas

Bearish Evidence

Rinkos nuotaikos

By Acuity

133 / 351 reitingas Sveikatos priežiūra

Naujienos nuotaikos

Neutral

Svyravimai

Žemiau vidurkio

Naujienų apimtis (RCV)

Vidutinis

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Ionis Pharmaceuticals Inc

Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy. It also develops medicines for various indications that are in phase 3 study, including Eplontersen as a monthly self-administered subcutaneous injection to treat all types of ATTR; Olezarsen for patients with FCS and severe hypertriglyceridemia (SHTG); Donidalorsen for patients with hereditary angioedema; ION363 for patients with amyotrophic lateral sclerosis; Tofersen to inhibit the production of superoxide dismutase 1; Pelacarsen for patients with established cardiovascular disease and elevated lipoprotein(a); and Bepirovirsen to inhibit the production of viral proteins associated with hepatitis B virus. In addition, the company develops IONIS-FB-LRx to inhibit the production of complement factor B and the alternative complement pathway; and ION224 to reduce the production of diacylglycerol acyltransferase 2. It has a strategic collaboration with Biogen for the treatment of neurological disorders; and collaboration and license agreement with Metagenomi, Inc, AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis, Roche, Swedish Orphan Biovitrum AB, and PTC Therapeutics. The company was incorporated in 1989 and is based in Carlsbad, California.
help-icon Live chat